Find Your Funding Opportunity

Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
Bookmarked grants will display in your Account Setting page

Service Source Final Application Due Date Funding Available Match Required
Health Care Federal
HHS
08-18-2026 N/A No Match
Required
  • Service
  • Source
  • Final Application Due Date
  • Funding Available
  • Match Required
Status
  • Past
  • Current
  • Forecasted
    • Opportunity Type Discretionary
    • CFDA

      93.121 -- Oral Diseases and Disorders Research

      93.213 -- Research and Training in Complementary and Integrative Health

      93.242 -- Mental Health Research Grants

      93.273 -- Alcohol Research Programs

      93.279 -- Drug Abuse and Addiction Research Programs

      93.853 -- Extramural Research Programs in the Neurosciences and Neurological Disorders

      93.865 -- Child Health and Human Development Extramural Research

      93.866 -- Aging Research

      93.867 -- Vision Research

    Description

    Reissue of PAR-18-546. The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry to the Development stage, to advance a single development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Alternatively, projects can enter at the Development stage and progress in a shorter period to IND enabling toxicology studies and phase I clinical testing. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

    Eligibility
    • IHE
    • Local Government
    • Non-Profit
    • Other
    • State Government
    • Tribal Government
    Additional Eligibility Information

    Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

    Key Date(s)
    • November 02, 2023: Last Updated Date
    • November 02, 2023: Posted Date
    • August 18, 2026: Current Closing Date for Applications
    • August 18, 2026: Application Due Date
    • September 23, 2026: Application Archive Date
    Contact Information

    NIH Grants Information

    grantsinfo@nih.gov

    DROP US A LINE

    Feedback Feedback

    Your opinion is important to us

    • How would you rate your overall experience on our website?

    • How easy is it to find the information you need?

    • How do you rate the look & feel of our website?

    • How could we improve our website?